Bay or Baylike Regions of Polycyclic Aromatic Hydrocarbons Were Potent Inhibitors of Gap Junctional Intercellular Communication

Liliane M. Weis,1 Alisa M. Rummel,2 Susan J. Masten,1 James E. Trovko,2,3 and Brad L. Upham3

1Department of Environmental and Civil Engineering; 2National Food Safety and Toxicology Center; and 3Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI 48824 USA

Many polycyclic aromatic hydrocarbons (PAHs) are known carcinogens, and a considerable amount of research has been devoted to predicting the tumor-initiating potential of PAHs based on chemical structure. However, there has been little research into the effects of PAHs on the epigenetic events of tumor promotion and no structural correlation has been made thereof. Gap junctional intercellular communication (GJIC) activity was used in this study as an epigenetic biomarker to determine the structure-activity relationships of twelve different PAHs. The PAHs used were naphthalene, 1-methylnaphthalene, 2-methylnaphthalene, anthracene, 1-methylanthracene, 2-methylanthracene, 9-methylanthracene, 9,10-dimethylanthracene, phenanthrene, fluorene, 1-methylfluorene, and fluoranthene. Results showed that PAHs containing bay or baylike regions inhibited GJIC more than did the linear PAHs. The nonnaphthalene PAHs were not cytotoxic as determined by a vital dye uptake assay, but the naphthalene compounds were cytotoxic at the higher doses, indicating that the down regulation of GJIC by these naphthalenes could be a consequence of general membrane damage. Inhibition of GJIC by all the inhibitory PAHs was reversed when the cells were refreshed with PAH-free growth medium. Inhibition of GJIC occurred within 0.5–5 min and correlated with the aqueous solubility of the PAHs. The present study revealed that there are structural determinants of epigenetic activity as determined by GJIC activity. Key words: anthracenes, fluoranthene, fluorene, gap junctional intercellular communication, methylnaphthalenes, methylfluorene, methylnaphthalene, naphthalene, phenanthrene, polycyclic aromatic hydrocarbons.

Environ Health Perspect 106:17–22 (1998). [Online 2 January 1998]
http://ehpnet1.niehs.nih.gov/docs/1998/106p17-22weis/abstract.html

Polycyclic aromatic hydrocarbons (PAHs) are common environmental pollutants formed during incomplete combustion; they are also found in petroleum products and in wood-processing chemical mixtures. The PAHs are of concern because they have been shown to induce tumors in experimental animals (1). Occupational exposures of humans to PAH-containing products have been linked to cancer as early as 1775, when increased scrotal cancer in chimney sweeps was attributed to exposure to soot (2). Exposure to high levels of PAHs appears to result in an increased risk of mortality from lung, prostate, and kidney cancers as documented in exposure studies in coke oven workers and residents exposed to unvented coal or wood smoke (3–5). Considerable research has been devoted to predicting the carcinogenicity of PAHs based on the correlation of chemical structure and genotoxicity (6–8). Although the first stage of cancer (tumor initiation) often requires genotoxic/mutagenic events (9,10), the second stage of cancer (tumor promotion) is a consequence of a series of reversible epigenetic events (10–13). Therefore, epigenetic data should also play a pivotal role in predicting the carcinogenicity of PAHs based on chemical structure; however, such data of epigenicity is lacking in the literature.

Extracellular, intracellular, and intercellular communication play a crucial role in the epigenetic changes of gene expression (14–18). In particular, intercellular communication through gap junctions provides the crucial link of a cell with its neighboring cells, thus enabling individual cells to exist communally as a multicellular organism (15–20). Because most cancer cells do not behave in harmony with their neighbors, it is not surprising that the down regulation of gap junctional intercellular communication (GJIC) results in uncontrolled cellular growth leading to the development of tumors (15,20). Evidence supports the hypothesis that inhibited GJIC activity is related to carcinogenesis (19–22); most, if not all cancer cells, have dysfunctional GJIC; endogenous and exogenous tumor-promoting agents reversibly inhibit GJIC; oncogenes down regulate GJIC; tumor suppressor genes and antitumor promoters up regulate GJIC; and transfection of gap junction genes into GJIC-deficient and tumorigenic cells restores GJIC and normal growth regulation.

Understanding of the molecular basis of the carcinogenicity of PAHs will therefore need to include a study of epigenetic events such as those that affect GJIC. For example, newborn mice treated with three intraperitoneal doses of fluoranthene showed an increase of lung and liver tumors (23,24), but in other studies, there was no evidence of tumor-initiating activity in experimental animals (J) or in vivo genotoxicity, as assessed using the mouse bone marrow micronucleus and rat liver unscheduled DNA synthesis assays (25). Although the tumor-promoting activity of fluoranthene has not been determined, fluoranthene was shown to inhibit GJIC in a rat liver epithelial cell line (26), which indicates that fluoranthene may be a tumor promoter because of its epigenetic properties.

Upham et al. (27) showed a structural relationship between various monomethyl isomers of anthracene and GJIC activity. The inhibitory monomethyl isomers of anthracene possess a baylike region, whereas anthracene and the monomethyl isomer with no baylike region do not inhibit GJIC. The purpose of this study was to determine if PAHs with a baylike region (formed from methyl substitution) and PAHs containing an actual bay region (formed by fused rings) are more potent inhibitors of GJIC than the more linear PAH analogues and how these compounds compare with the anthracenes. The description of bay versus baylike regions is shown in Figure 1. The aromatic hydrocarbons used in this study are naphthalene, 1-methylnaphthalene, 2-methylnaphthalene, anthracene, 1-methylanthracene, 2-methylanthracene, 9-methylanthracene, 9,10-dimethylanthracene, phenanthrene, fluorene, 1-methylfluorene, and fluoranthene. The basic structures of these chemicals are shown in Figure 1.

These PAHs are some of the most prominent compounds of the very tumorigenic portion of cigarette smoke condensates (28). In particular, the most abundant PAHs in this neutral fraction were shown to be methylated anthracenes and phenanthrenes (1,494 ng/cigarette), and most of the remaining PAHs are benzo(a)pyrene, methylchrysene, chrymesne, fluoranthene,

Address correspondence to B.L. Upham, Department of Pediatrics and Human Development, Michigan State University, B240 Life Sciences, East Lansing, MI 48824 USA.

We wish to thank Robbyn Davenport for her excellent word processing skills in preparing the manuscript. This research was funded by the National Institute of Environmental Health Sciences (Superfund grant #P42 ES04911-07), the National Food Safety and Toxicology Center at Michigan State University, and the United States Air Force (grant USAFOSR F49620-97-1-0022).

Received 11 July 1997; accepted 15 September 1997.
phenanthrene, methylpyrene, anthracene, and phenanthrene, ranging in concentrations of 24–360 ng/cigarette (28).

Materials and Methods

**Chemicals.** Anthracene, 1-methylanthracene, 2-methylanthracene, 9-methylanthracene, 9,10-dimethylanthracene, naphthalene, 1-methylnaphthalene, 2-methylnaphthalene, fluorene, fluoranthene, 1-methylfluorene, and formaldehyde (37%) were obtained from Aldrich Chemical Co., Inc. (Milwaukee, WI). Phenanthrene, neutral red, and lucifer yellow were obtained from Sigma Chemical Co. (St. Louis, MO). Acetonitrile was obtained from EM Science (Gibbstown, NJ).

**Stock solutions.** PAHs were dissolved in 100% acetonitrile. Concentrations of stock solutions ranged from 5 to 30 mM, depending upon the solubility of the compound in acetonitrile. The volumes of the stock solutions that were added directly to the culture medium in each plate ranged from 2 to 35 μl. Vehicle controls were added to the cells at a volume of acetonitrile equivalent to the volume of PAH stock solution used. Acetonitrile was used because it is nontoxic and noninhibitory up to 2% (v/v) (26). Cells were exposed to a maximum of 1.8% (v/v) acetonitrile in culture medium. Due to the low aqueous solubility of the chemicals, the maximum concentration of most of the PAHs achievable in the culture medium was 350 μM.

**Cell cultures.** WB-F344 rat liver epithelial cell lines were obtained from J.W. Grisham and M.S. Tsao of the University of North Carolina (Chapel Hill, NC) (29). This cell line was used because much of the in vivo tumor promotion assays were done in rat liver, specifically in the Fischer 344 rats. The WB-344 cell line was designed to match in vitro work in a liver cell line from the same strain of rat. Also the WB-344 cell line is an immortalized diploid cell line that is nontransformic (29), has been well characterized around the world for its expressed gap junction genes and its ability to perform GJIC via all available techniques (19), has been tested with all kinds of tumor-promoting chemicals for their ability to block GJIC (19), and has been tested for the ability of growth factors and oncogenes to modulate GJIC (19).

Cells were cultured in 2 ml D-medium (formula no. 78-5470EG; Gibco Laboratories, Grand Island, NY) and supplemented with 5% fetal bovine serum (Gibco) and 50 μg/ml gentamicin (Gibco). The cells were grown in 35-mm diameter plastic petri dishes (Corning Glass Works, Corning, NY) and incubated at 37°C in a humidified atmosphere containing 5% CO₂ and 95% air. Bioassays were conducted on confluent cells that were obtained after 2–3 days of growth.

**Chemical treatments.** In the dose-response experiments, cells were exposed to different doses of the target compound for a set period of time, and threshold values for inhibitory doses were determined. In the time-response experiments, cells were exposed for various lengths of time to the target compound at a dose that was known to cause inhibition of GJIC.

In the time recovery experiments, cells were exposed to the target compound at a dose and for a length of time that caused inhibition of GJIC. Following chemical exposure, the PAH-containing medium was discarded and cells were washed five times with phosphate-buffered saline (PBS) and recultured in fresh PAH-free medium for various incubation times.

**Gap junctional intercellular communication.** GJIC was determined by using the scrape loading/dye transfer (SL/DT) assay adapted from El-Fouly et al. (30). Following the chemical exposures, cells were rinsed five times with PBS, and then approximately 1 ml 0.05% lucifer yellow dye (dissolved in PBS) was added to the cells. A surgical steel blade was used to make 8–10 scrapes through the monolayer of cells. After a 3-min incubation time at room temperature, the dye was discarded and the cells were rinsed five times with PBS and then fixed with approximately 0.5 ml 4% formalin. The SL/DT assay was done immediately following chemical exposure or, with respect to the time recovery experiments, following the reincubation period.

The migration of the dye in the cells was observed using a Nikon epifluorescence phase microscope, illuminated with an Osram HBO 200 W lamp and equipped with a 35mm camera (Nikon Inc., Nikon, Japan). Photographs of the cells were taken at a magnification of 200×. Ten equally spaced measurements (1 cm apart) were made on each 200× photograph, and the distance the dye traveled was measured perpendicularly to the cut. The average distance of dye migration was determined by averaging these 10 measurements and was normally 200 μm. GJIC was assessed by comparing the distance the dye traveled in the chemically treated cells to the distance the dye traveled in the vehicle controls. GJIC was reported as a fraction of the control (FOC). An FOC value of approximately 1.0 indicates that the neutral red dye was equivalent to that of the vehicle control. An FOC value of less than 1.0 indicates less neutral red uptake as compared to the controls, and a cytotoxic response to the target compound at the concentrations tested.

**Data analysis.** All data were compared to and expressed as an FOC. Each value represents the mean FOC of at least three measurements from three different culture plates ± the SD at the 95% confidence interval.
Inhibition of GJIC by PAHs

Results

Dose response. Naphthalene and 2-methyl-naphthalene partially inhibited GJIC at a dose of 350 μM (Fig. 2). 1-Methyl-naphthalene completely inhibited GJIC at a concentration of 225 μM (Fig. 2). Anthracene and 2-methylnaphthalene did not inhibit GJIC up to a dose of 350 μM (Fig. 3). Phenanthrene, 1-methylnaphthalene, 9-methylnaphthalene, and 9,10-dimethylnaphthalene inhibited GJIC at 70 μM (Fig. 3). Fluoranthene and 1-methylfluorene were more inhibitory of GJIC than was fluorene (Fig. 4). Fluoranthene and fluorene inhibited GJIC at 65 μM, whereas fluorene inhibited GJIC at 100 μM.

Cytotoxicity. The 3-ring PAHs and fluorene-type PAHs were not cytotoxic (Fig. 5) at doses that inhibited GJIC, whereas the methylnaphthalenes were cytotoxic at doses that were only slightly higher in concentration than the dose which was inhibitory to GJIC (Fig. 6). Increased incubation time of 1-methylnaphthalene at a sublethal dose resulted in an increased cytotoxic response (Fig. 7).

Time recovery. When the cells were allowed to recover in fresh medium in the absence of the target compound, GJIC was restored significantly within the first hour. GJIC was completely restored within 4 hr (Fig. 8). Recovery was similar for all of the compounds tested.

Time response. Both 1-methylnaphthalene and 2-methylnaphthalene inhibited GJIC within the first 30 sec of exposure to the target compound (Fig. 9). Inhibition of GJIC in cells treated with the 3-ring and fluorene-type PAHs occurred within 5 min (Fig. 9). A linear relationship was observed between the log octanol/water partition coefficient (log $K_{ow}$) and the time required for each PAH to inhibit GJIC at a value of 0.5 of the FOC. The time of inhibition at 0.5 FOC was calculated using the statistically determined values of a four parameter logistic function to describe a sigmoidal curve (Eq. 1), which was determined for each of the PAHs (Table 1), and solving for x when $f(x) = 0.5$.

$$f(x) = \frac{a}{1 + e^{(x-c)}} + d$$

$f(x)$ is the fraction of the control, $x$ is the incubation time of the chemical with the cells in minutes, $a$ is the range of FOC, $b$ is the slope coefficient, $c$ is the inflection point of the curve, and $d$ is the minimum FOC. Similarly, a linear regression of the relationship of log $K_{ow}$ versus the dose at 0.5 FOC was determined for all 12 of the PAHs, generating the following equation:

$$\log K_{ow} = -0.0015(\mu M) + 4.81$$

with an $r^2 < 0.081$. Clearly there was not a linear relationship between log $K_{ow}$ and dose. Because anthracene and 2-methylnaphthalene did not inhibit GJIC, we used the highest dose tested; this is why we reported the $r^2$ value as less than 0.081.

Discussion

We have specifically compared a structural–functional relationship between the bay or baylike regions of PAHs and GJIC. The term bay region refers to the pocket formed by the sterically hindered region created by an angular benzo ring (Fig. 1). Similarly, the term baylike region is used to describe the angular pocket formed at the top of the benzene ring by a methyl group (Fig. 1). However, we should note that the bay and baylike regions discussed are not those formed by the well-known DNA reactive diol epoxides, but rather the unmetabolized...
parent structure. Our focus was on the epigenetic effects of PAHs, which does not require the metabolic activation of a PAH to a chemically more reactive electrophilic compound.

The naphthalene-type PAHs inhibited GJIC in a shorter time period (Fig. 2) and were cytotoxic at higher doses and incubation times (Fig. 6, Fig. 7), when compared to the other PAHs (Fig. 5). The effect of naphthalene-type PAHs on GJIC could partially be due to a greater cytotoxicity, but the magnitude of inhibition was greater with 1-methylnaphthalene, which contained a baylike region. Naphthalene was shown to induce oxidative stress in rats (32); therefore, the cytotoxicity of the naphthalenes could be a consequence of oxidative stress. However, oxidative stress at nontoxic levels is also known to modulate GJIC (33-35).

The inhibitory effect of PAHs containing bay or baylike regions on GJIC was more pronounced with the 3-ring and fluorene-type PAHs (Fig. 3, Fig. 4). These PAHs were not very cytotoxic, even at higher doses (Fig. 5). Multiple baylike regions do not significantly increase the potency of the compound to inhibit GJIC when compared to a compound that contains a single baylike region. For example, 9-methylnaphthalene and 9,10-dimethylnaphthalene possess multiple baylike regions, while 1-methylnaphthalene possesses only one baylike region; yet, these compounds all had similar dose-response curves (Fig. 3). Also, there were no major differences in dose response between bay and baylike regions of fluorene-type versus the 3-ring PAHs (Fig. 3, Fig. 4). Furthermore, no significant differences were observed in the inhibition of GJIC by PAHs containing bay versus baylike regions. For example, phenanthrene and fluoranthene, which contain bay regions, exhibited similar dose-response curves as compared to 1-methylnaphthalene, 9-methylnaphthalene, and 1-methylfluorene, which contain baylike regions (Fig. 3, Fig. 4). However, fluorene, which contains no bay region, did inhibit GJIC, albeit at a higher dose (Fig. 4). Apparently, the pentyl ring of fluorene increased the toxic effect of the 3-ring PAH. Inhibition of GJIC by these PAHs was also a reversible process (Fig. 8) which is consistent with the reversible nature of tumor promotion in vivo (19).

Inhibition occurred in a short period of time for all of the PAHs (Fig. 9), indicating that the gap junctions are being modified at the posttranslational level. The more water-soluble GJIC-inhibiting PAHs, which are the PAHs with lower log Kow values, down regulated GJIC in a shorter time than the less water-soluble PAHs (Fig. 10). This linear relationship of log Kow versus inhibition time of a PAH (Fig. 10) implies more efficient diffusion and greater bioavailability of the more water soluble PAHs to the cell plasma membrane receptor.

The tumor-promoting activity of the PAHs we tested has not been extensively studied. Nevertheless, there is some evidence that PAHs containing bay regions are cocarcinogenic in animals, as illustrated by the fact that the carcinogenicity of benzo(a)pyrene was enhanced by phenanthrene, fluoranthene, and 3-methylcholanthrene (36-38). Also, the promoting effect of benzo(a)pyrene was enhanced by benz(a)anthracene, phenanthrene, fluoranthene, and 3-methylcholanthrene (38-40). These cocarcinogenic PAHs, all of which contain bay and baylike regions, are not complete carcinogens. In particular, fluoranthene and phenanthrene have been shown not to be tumor initiators (7,25,37,41) and benz(a)anthracene exhibits only weak tumor initiating activity (42).

The methylated forms of PAHs have also been shown to be more carcinogenic.
than their parent counterparts (7.43–50). The increased carcinogenicity of methylated versus the unmethylated PAHs is important, considering the growing evidence that bioalkylation plays an important role in the activation pathway of converting noncarcinogenic PAHs to carcinogenic PAHs (50–52). Methyl substitution, which results in the formation of bayllike regions, occurs in vitro at the mesoanathracenic positions (43, 50, 51, 53). Methylated PAHs can undergo further metabolism in which microsomal enzymes hydroxylate methyl groups (43, 54, 55) and hepatic sulfotransferases catalyze the formation of sulfate esters with the hydroxymethyl groups (55–58).

All of the studies done to determine the carcinogenicity of methylated PAHs and their oxidized products focused on either mutagenicity or complete carcinogenicity. However, mutagenicity of strong electrophiles does not always correlate with carcinogenicity, and complete carcinogens must also induce tumor promotion through a series of epigenetic events (59). For example, 5-methylchrysene is more carcinogenic than the unmethylated parent compound but the higher carcinogenic potential of 5-methylchrysene and its more electrophilic metabolites could not be related to its mutagenic potential (60). Thus, the fraction of methylated PAHs that are not further metabolized into strong electrophiles can still exert a tumorigenic effect at the promotion/epigenetic stage of cancer. Some studies have shown PAHs to be epigenetically active, such as benzo(a)pyrene and 7, 12-dimethylbenz(a)anthracene, which can increase intracellular Ca²⁺ and cell proliferation in primary human epithelial cells (62). Benzo(a)pyrene has also been shown to induce the proliferation of vascular smooth muscle cells that do not involve the mutational activation of c-Ha, c-Ki, or N-ras genes (62). Determining structure–activity relationships relative to intracellular and intercellular communication processes involved in the promotional stages of cancer should help in predicting the carcinogenicity of the many different PAHs in our environment.

Although in vitro results are difficult to extrapolate to in vivo situations pertaining to the carcinogenic risk of a chemical, some useful information can be obtained from in vitro experiments. For instance, in vitro assays are usually better suited for studying structure–activity relationships at a more mechanistic level, which can increase our ability to predict the potency of tumor promoters based on chemical structure. Also, out in vitro results show a threshold level of no effect, which suggests that it should be possible to determine threshold levels when conducting in vivo experiments. Further, these in vitro studies can ultimately reduce the extent of whole-animal testing. In particular, our results show that the effects of dose, time response, and time of recovery of the 3-ring and fluorene-type PAHs on GJIC were similar (Fig. 3, Fig. 4, Fig. 8, Fig. 9). These results suggest a similar mechanism of action. Therefore, in vivo experiments could be minimized by randomly selecting one or two of these chemicals rather than testing all of them.

REFERENCES

1. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol 32: Polynuclear Aromatic Compounds, Part 1: Chemical, Environmental and Experimental Data. Lyon: International Agency for Research on Cancer, 1983.
2. Pett P. Cancer scroti. The Chirurgical Works of Percivall Pott. First American edition from the last London edition. Philadelphia, PA: James Webster, 1819;291–295.
3. Lloyd JW. Long-term mortality study of steelworkers. V. Respiratory cancer in coke plant workers. J Occup Med 13:53–68 (1971).
4. Redmond CK, Stroblno BP, Cypress RH. Cancer experience among coke-by-product workers. Ann N Y Acad Sci 271:102–115 (1976).
5. IARC. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Vol. 34: Polynuclear Aromatic Compounds: Industrial Exposures in Aluminum Production, Coal Gasification, Coke Production and Iron and Steel Foundling. Lyon: International Agency for Research on Cancer, 1984.
6. Jerina DM, Yagi H, Lehr RE, Thakker DR, Schaefer-Ridder M, Karle JM, Levin W, Wood AW, Chang RL, Conney AH. The bay-region theory of carcinogenesis by polycyclic aromatic hydrocarbons. In: Polycyclic Hydrocarbons and Cancer. Vol 1, Environment, Chemistry, and Metabolism (Galboun H, Tao POP, eds). New York: Academic Press, 1978:173–188.
7. Hoffman D, Lavoie EJ, Hecht SS. Polynuclear aromatic hydrocarbons: effects of chemical structure on tumorigenicity. In: Polynuclear Aromatic Hydrocarbons: Physical and Biological Chemistry (Cooko M, Dennis AJ, Fisher GL, eds). Columbus, OH: Battelle Press, 1982:1–19.
8. Silverman BD,Lewis JP. Diol-epoxide reactivity of methylated polycyclic aromatic hydrocarbons (PAH): ranking the reactivity of the positional monomethyl isomers. In: Polynuclear Aromatic Hydrocarbons: Physical and Biological Chemistry (Cooko M, Dennis AJ, Fisher GL, eds). Columbus, OH: Battelle Press, 1982:23–50.
9. Cooper GM. Classification and development of neoplasms. In: Elements of Human Cancer, Boston, MA: Jones and Barthlett Publishers, 1992:15–30.
10. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res Suppl 51(18 suppl):5023–5044 (1991).
11. Boustwell RK. Some biological aspects of skin carcinogenesis. Prog Exp Tumor Res 43:207–230 (1994).
12. Holliday R. DNA methylation and epigenetic defects in carcinogenesis. Mutat Res 181:215–217 (1987).
13. Boyd JA, Barrett JC. Genetic and cellular basis of multistage carcinogenesis. Pharmacol Ther 40:469–486 (1990).
14. Trosko JE Chang CC, Madhukar BV. The role of modulated gap junction function: the scientific basis of epigenetic toxicology. In: Vitro Toxicol 3:39–29 (1983).
15. Trosko JE, Chang CC, Madhukar BV. In vitro analysis of modulators of intercellular communication: implications for biologically based risk assessment models for chemical exposure. Toxicol In Vitro 4:633–643 (1990).
16. Trosko JE, Chang CC, Madhukar BV, Klaunig JE. Chemical, oncogene and growth factor inhibition of gap junctional intercellular communication: an integrative hypothesis. Pathobiol 58:265–278 (1990).
17. Trosko JE, Chang CC, Madhukar BV. The role of modulated gap junctional intercellular communication in epigenetic toxicology. Risk Anal 14:303–312 (1994).
18. Trosko JE, Madhukar BV, Chang CC. Endogenous and exogenous modulation of gap junctional intercellular communication: toxicological and pharmacological implications. Life Sci 51:19 (1992).
19. Yamaski H, Naus CCC. Role of connexin genes in growth control. Carcinogenesis 17:1199–1213 (1996).
20. Trosko JE, Chang CC. Nongenotoxic mechanisms in carcinogenesis: role of inhibited intercellular communication. In: Banbury Report 31: New Directions in the Qualitative and Quantitative Aspects of Carcinogen Risk Assessment (Hart RW, Hoegar FD, eds). Cold Spring Harbor, NY:Cold Spring Harbor Laboratory Press, 1989:129–170.
21. Trosko JE, Chang CC, Madhukar BV. Modulation of gap junction intercellular communication by tumor promoting chemicals, oncogenes and growth factors during carcinogenesis. In: Modern Cell Biology, Vol. 7: Gap Junctions (Hertzberg EL, Johnson RD, eds). New York: Alan R. Liss, 1988:435–448.
22. Busby WF, Jr, Goldman ME, Newberne PM, Wogan DN. Tumorogenicity of fluoranthene in a newborn mouse lung adenoma bioassay. Carcinogenesis 5:1311–1316 (1984).
23. Wang J-S, Busby WF, Jr. Induction of lung and liver tumors by fluoranthene in a preweaning CD-1 mouse bioassay. Carcinogenesis 14:1871–1874 (1993).
24. Stocker KJ, Howard WR, Statham J, Proudlock RJ. Assessment of the potential in vivo genotoxicity of fluoranthene. Mutagenesis 11:493–498 (1996).
25. Upaham BL, Masten SA, Lockwood BR, Trosko JE. Nongenotoxic effects of polycyclic aromatic hydrocarbons and their ozonation by-products on the intercellular communication of rat liver epithelial cells. Fundam Appl Toxicol 23:470–475 (1994).
26. Upaham BL, Weis LM, Rummel AM, Masten SJ, Trosko JE. The effects of anthracene and methylated anthracenes on gap junctional intercellular communication in rat liver epithelial cells. Fundam Appl Toxicol 34:250–256 (1996).
28. Saverson RF, Snook, ME, Higman HC, Chortyk OT, Akin FJ. Isolation, identification, and quantification of the polynuclear aromatic hydrocarbons in tobacco smoke. In: Chemistry, Metabolism and Carcinogenesis (Freudenthal RJ, Jones PW, eds). New York: Raven Press, 1976;253–270.

29. Tsao MS, Smith JD, Nelson KG, Grisham JWA. Diploid epithelial cell line from normal adult rat liver with phenotypic properties of oval cells. Exp Cell Res 154:38–52 (1984).

30. El-Fouly NH, Trokso JE, Chang CC. Scrape-loading and dye transfer. A rapid and simple technique to study gap junctional intercellular communication. Exp Cell Res 168:422–430 (1987).

31. Bornenfrend E, Puerner J. Toxicology determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett 24:119–134 (1985).

32. Vuchetich P, Bagchi D, Bagchi M, Hassoun EA, Tang L, Stohs SJ. Naphthalene-induced oxidative stress in rats and the protective effects of vitamin E succinate. Free Radical Biol Med 21:577–590 (1996).

33. Upham BL, Kang K-S, Cho H-Y, Trokso JE. Hydrogen peroxide inhibits gap junctional intercellular communication in glutathione sufficient but not glutathione deficient cells. Carcinogenesis 18:37–42 (1997).

34. Fu J, Engman LA, Rao JA. Reductive chalcogen-containing glutathione peroxidase mimetics and antioxidants inhibit tumor promoter–induced down regulation of gap junctional intercellular communication between W59/F344 rat liver epithelial cells. Carcinogenesis 16:1815–1824 (1995).

35. Hu J, Speisky H, Cotgreave IA. The inhibitory effects of boldine, quinic, and propolol on TPA-induced down regulation of gap junction function. Relationships to intracellular proteases, protein kinase C translocation and connexin43 phosphorylation. Biochem Pharmacol 50:1635–1643 (1995).

36. Rusch HP, Kline BE, Baumann CA. The nonadditive effect of ultraviolet light and other carcinogenic procedures. Cancer Res 2:183–188 (1942).

37. Roe FJ. Effect of phenanthrene on tumor-initiation by 3,4-benzpyrene. Cancer 18:503–508 (1963).

38. van Duuren BL, Goldschmidt BM. Carcogenic and tumor-promoting agents in tobacco carcinogenesis. J Natl Cancer Inst 56:1237–1242 (1976).

39. Stainer PE, Falk HL. Summation and inhibition effects of weak and strong carcinogenic hydrocarbons:1,2-benzanthracene, chrysen, 1,2,5,6-dibenzanthracene, and 2-methylnaphthanthrene. Cancer Res 11:56–63 (1951).

40. Falk HL, Kotin P, Thompson S. Inhibition of carcinogenesis. Arch Environ Health 19:169–179 (1964).

41. Hoffmann D, Rathkamp G, Nasnow S, Wynder EL. Fluoranthene: quantitative determination in cigarette smoke, formation by pyrolysis, and tumor-initiating activity. J Natl Cancer Inst 49:1165–1175 (1972).

42. Norpork H, Kemenia A, Jacob J, Schümann C. The influence of 18 environmentally relevant polycyclic aromatic hydrocarbons and Cophen A50 as liver monooxygenase activity, the mutagenic activity of benz[a]anthracene in the Ames test. Carcinogenesis 5(6):747–752 (1984).

43. Myers SR, Blake JW, Flesher JW. Bioactivation and bioxidation of anthracene, in vitro and in vivo. Biochim Biophys Acta 1513(1):1441–1445 (1998).

44. Hecht SS, Loy M, Hoffman D. On the structure and carcinogenicity of the methylychrysenes. In: Carcinogenesis - Vol 1 Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism and Carcinogenesis (Freudenthal RJ, Jones PW, eds). New York: Raven Press, 1976;325–340.

45. Slaga T-J, Bowden GT, Scribner JD, Boutwell RK. Dose–response studies on the ability of 7,12-dimethylbenz[a]anthracene and benz[a]anthracene to initiate skin tumors. J Natl Cancer Inst 53:1327–1340 (1974).

46. Slaga TJ, Iyer RP, Lyga W, Secrist A, Daub GH, Harvey RG. Comparison of the skin tumor-initiating activities of dihydrodiol, diol epoxides, and methylated derivatives of various polycyclic aromatic hydrocarbons. In: Polynuclear Aromatic Hydrocarbons: Chemistry, Metabolism and Biological Effects (Bjerstedt A, Dennis AJ, eds). Columbus, OH: Battelle Press, 1980;753–769.

47. LaVoise EJ, Coleman DT, Rice JE, Geddie NG, Hoffman D. Tumor-initiating activity, mutagenicity, and metabolism of methylated anthracenes. Carcinogenesis 6(10):1483–1488 (1985).

48. LaVoise EJ, Tulley-Freiler L, Bedenko V, Hoffman D. Mutagenicity, tumor-initiating activity, and metabolism of methylphenanthrenes. Cancer Res 41:3441–3447 (1981).

49. Kunihara T, Motomatsu N, Pang G-L, Higano M, Kiguchi K, Molinar J. Correlations between topological resonance energy of methyl-substituted benzenoid derivatives, benzo[alpha]pyrenes and chrysene, and their carcinogenic or anti-tumor activities. Anticancer Res 16:2757–2766 (1996).

50. Flesher JW, Myers SR, Stansbury KH. The site of substitution of the methyl group in the bioactivation of benz[a]pyrene. Carcinogenesis 11:493–496 (1990).

51. Flesher JW, Myers SR. Rules of molecular geometry for predicting carcinogenic activity of unsubstituted polynuclear aromatic hydrocarbons. Teratog Carcinog Mutagen 11:41–54 (1991).

52. Flesher JW, Myers SR. Bioactivation of benz[a]anthracene as a biochemical probe for carcinogenic activity: lack of bioactivation in a series of noncarcinogenic polynuclear aromatic hydrocarbons. Drug Metab Dispos 18:163–167 (1991).

53. Myers SR, Flesher JW. Bioactivation of benz[a]anthracene, 7-methylbenz[a]anthracene and 12-methylbenz[a]anthracene in rat lung cytosol preincubations. Biochem Pharmacol 41:1683–1690 (1991).

54. Yang SK, Chou MW, Fu PP. Microsomal oxidations of methyl-substituted and unsubstituted aromatic hydrocarbons of monomethylbenz[a]anthracene. In: Polynuclear Aromatic Hydrocarbons: Chemical Analysis and Biological Fate (Cooke M, Dennis AJ, eds). Columbus, OH: Battelle Press, 1980;235–264.

55. Watabe T, Ishizuka T, Isobe M, Ozawa NA. 7-Hydroxymethyl sulfite ester as an active metabolite of 7,12-dimethylbenz[a]anthracene. Science 215:403–405 (1982).

56. Surh YJ, Liem A, Miller EC, Miller JA. Metabolic activation of the carcinogen 6-hydroxymethylbenz[a]pyrene: formation of an electrophilic sulfuric acid ester and benzylic DNA adducts in rat liver in vivo and in reactions in vitro. Carcinogenesis 10:1519–1528 (1989).

57. Surh YJ, Liem A, Miller EC, Miller JA. 7-Sulfamethyl-12-methylbenz[a]anthracene is an electrophilic mutagen, but does not appear to play a role in carcinogenesis by 7,12-dimethylbenz[a]anthracene or 7-hydroxymethyl-12-methylbenz[a]anthracene. Carcinogenesis 12:339–348 (1991).

58. Surh YJ, Liem A, Miller EC, Miller JA. The strong hepatocarcinogenicity of the electrophilic and mutagenic metabolites 6-sulfomethylbenz[a]pyrene and its formation of benzylic DNA adducts in the liver of infant male B6C3F1 mice. Biochim Biophys Acta 172:85–91 (1990).

59. Troso JE. Challenge to the simple paradigm that ‘carcinogens’ are ‘mutagens’ and to the in vitro and in vivo assays used to test the paradigm. Mutat Res 372:245–249 (1997).

60. Cheung YL, Gray TJB, Loanides C. Mutagenicity of chrysen, its methyl and benzo derivatives, and their interactions with cytochromes P-450 and the Ah receptor: relevance to their carcinogenic potency. Toxicol Lett 41:1–19 (1990).

61. Tanheimer SL, Bartom SL, Ether SP, Burchiel SW. Carcinogenic polycyclic aromatic hydrocarbons increase intracellular Ca2+ and cell proliferation in primary human mammary epithelial cells. Carcinogenesis 18:1177–1182 (1997).

62. Zhang Y, Ramos KS. The induction of proliferative vascular smooth muscle cell phenotypes by benz[a]pyrene does not involve mutational activation of ras genes. Mutat Res 372:285–292 (1997).

63. Mackay D, Shu WY, Ma KC, eds. Polynuclear aromatic hydrocarbons, polychlorinated dibenzo-furans. In: Illustrated Handbook of Physical-Chemical Properties and Environmental Fate for Organic Chemicals. VII. Chelsea, MI: Lewis Publishers, 1992:597.